



MITHRA PHARMACEUTICALS SA/NV SIGNS CONTRACT EXTENSION WITH PHARMACEUTICA SARL

Liège, Belgium 16 July 2015 – Mithra Pharmaceuticals today announces a contract extension with Pharmaceutica sarl for the distribution of its products in Lebanon. The contract has been extended by adding two products to the current product list: Tibolone 2,5 mg and Drospirenone/Ethinylestradiol (3mg/0.03mg).

A Distribution Agreement of Pharmaceuticals Products has been signed since 2009 between Pharmaceutica sarl and Mithra Pharmaceuticals for the distribution of its contraceptive pill Daphne and its pregnancy food supplement Mithra Bion (commercialised under the name “Suveal”).

The contract covers the order of 5.000 packs of Tibolone and 10.000 packs of Drospirenone/Ethinylestradiol.

“This contract extension continues an important relationship with an important distributor”, explains François Fornieri, CEO of Mithra Pharmaceuticals. “It reinforces our commitment to providing our existing customers easy access to high quality products.”

For more information, please contact:

Julie Dessart

Head of Communications

+32 4 349 28 22

+32 475 86 41 75

jdessart@mithra.com

Jean-Manuel Fontaine

Public Relations

+32 4 349 28 22

+32 476 96 54 59

jmfontaine@mithra.com

François Fornieri, CEO/ Steven Peters, CFO

+32 4 349 28 22

investorrelations@mithra.com

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on women’s health. Mithra’s mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women’s health

by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and generic products in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.